<DOC>
	<DOCNO>NCT00665639</DOCNO>
	<brief_summary>To determine efficacy safety daily dose IV micafungin versus IV caspofungin treatment esophageal candidiasis</brief_summary>
	<brief_title>Trial Two Dosing Regimens Micafungin Versus Caspofungin Treatment Esophageal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Esophageal candidiasis confirm endoscopy Negative pregnancy test female patient childbearing potential Pregnant nursing female patient Evidence liver disease Another active opportunistic fungal infection and/or receive acute systemic therapy opportunistic fungal infection Concomitant esophagitis cause herpes simplex virus cytomegalovirus Received oral topical antifungal agent within 48 hour systemic antifungal agent within 72 hour first dose study drug Known nonresponsive therapy prior systemic antifungal clinical trail Experienced &gt; 2 episode esophageal candidiasis require systemic antifungal therapy History anaphylaxis attribute echinocandin class antifungal</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Esophageal Candidiasis</keyword>
	<keyword>caspofungin</keyword>
</DOC>